內地第七批國家集採中選藥品涉60種平均降價48% 醫藥股榮辱互見 三葉草倒跌17%
內地第七批國家集採中選藥品涉60種,平均降價48%。醫藥股今天個別發展。內地疫情有所緩和,疫苗股跑輸,康希諾(06185.HK)也反覆兩連跌,高低見104.3元/91.1元,現報91.3元,續跌8.2%;康希諾A(688185.SH)也反覆挫8.7%至204元人民幣。
三葉草生物-B(02197.HK)反覆兩連跌兼失10天線(5.16元),現報5.54元,急降17%。開拓藥業-B(09939.HK)、復星醫藥(02196.HK)及歌禮-B(01672.HK)反覆跌逾5%-5.5%,後者兩連跌。藍籌石藥(01093.HK)失守10天及20天線,高低見10.06元/8.76元,現報9.19元,急吐8%;中生製藥(01177.HK)也反覆回吐2.6%報4.46元。
君實生物(01877.HK)反覆回吐8.8%報31.45元。信達生物(01801.HK)反覆回吐3.4%報29.6元。
然而,再鼎醫藥-B(09688.HK)三連升,最高見30.1元,現報29.05元,續漲6.8%;諾誠健華-B(09969.HK)及聯邦制藥(03933.HK)續升近2%-3.5%,報10.82元及4.21元。
藥明生物(02269.HK)反覆續升1.5%報50.9元;藥明康德(02359.HK)也反覆續升逾1%報77.65元。威高股份(01066.HK)反覆四連升,報11.54元,續升1.8%。
據《央視》報道,浙江及山東等地的第七批國家組織藥品集中帶量採購中選品種近日相繼落地。統計顯示,共涉及集採中選藥品60種,平均降價48%,明顯可降低患者負擔。山東省濟南市第七批藥品集採涉31個治療類別,囊括高血壓、糖尿病、抗感染、消化道疾病等常見病、慢性病用藥,並包括肺癌、肝癌、腎癌及腸癌等重大疾病用藥。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.